Titan: Will the Run Continue?

| About: Titan Pharmaceuticals, (TTNP)

TTNP: Titan has retreated somewhat from the highs of its most recent run, but the pending Probuphine confirmatory Phase III results keep it as a stock worth watching.

Increases of the past have seen TTNP slip back to below the $1.50 mark, but the retreat has not been that significant this go-round, at least not yet, which could be a sign that investors are taking the potential Probuphine news seriously this time.

There's been a lot of speculation surrounding the recent Deerfield credit announcement, especially since Titan relinquished 2.5% of Fanapt royalties to get the deal done. So investors will be looking for news, announcements or updates as to what Titan has in store for the short, mid and long term.

Still, I maintain my stance that the company will be bought out once the Probuphine results are known.

Any significant dips would be a time to add, in my opinion, but barring another drop to $1.30 or so, I like where we stand.

Keep an eye on it, I think we'll see a surge to above $2 leading into the results.

Disclosure: Long TTNP.

About this article:

Tagged: , , , Biotechnology
Problem with this article? Please tell us. Disagree with this article? .